Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of UCB0599 in Healthy Volunteers and Parkinson's Disease
NCT04875962Phase 1Completed
- Sponsor
- UCB
- Start
- May 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of minzasolmin in Parkinson's disease (PD) (4 cohorts), sponsored by UCB. Primary endpoint: Treatment-Emergent Adverse Events. Started May 2019; status: completed.
02
Drugs
minzasolmin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04875962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04875962.